Back to all studies
CompletedNCT00905307

Efficacy, Safety, and Tolerability of Oral OPC-34712 Once Daily and Aripiprazole Once Daily for schizophrenia

This study is completed in the United States, in Bulgaria, in Croatia, .... It is testing Efficacy, Safety, and Tolerability of Oral OPC-34712 Once Daily and Aripiprazole Once Daily for schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether OPC-34712 may be useful for adults experiencing schizophrenia.

What would participation involve?

Participants may receive OPC-34712, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Bulgaria, in Croatia, and in India.

Who is it mainly for?

This study appears to be mainly for adults with schizophrenia.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)
  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateJuly 2009
Recruitment status
Completed
Enrollment listed in the registry
459
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, Bulgaria, Croatia, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT00905307
Official title
A Phase 2, 6-Week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 Once Daily and Aripiprazole Once Daily for Treatment of Hospitalized Adult Patients With Acute Schizophrenia

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT00905307. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

Bulgaria · 6 sites
  • Study Site
    Burgas
    Site status: Not listed — confirm with the team
  • Study Site
    Kazanlak
    Site status: Not listed — confirm with the team
  • Study Site
    Pazardzhik
    Site status: Not listed — confirm with the team
  • Study Site
    Plovdiv
    Site status: Not listed — confirm with the team
  • Study Site
    Radnevo
    Site status: Not listed — confirm with the team
  • Study Site
    Rousse
    Site status: Not listed — confirm with the team
Croatia · 3 sites
  • Study Site
    Rijeka
    Site status: Not listed — confirm with the team
  • Study Site
    Split
    Site status: Not listed — confirm with the team
  • Study Site
    Zagreb
    Site status: Not listed — confirm with the team
India · 9 sites
  • Study Site
    Vijaywada, Andh Prad
    Site status: Not listed — confirm with the team
  • Study Site
    Visakhapatnam, Andh Prad
    Site status: Not listed — confirm with the team
  • Study Site
    Ahmedabad, Gujarat
    Site status: Not listed — confirm with the team
  • Study Site
    Bangalore, Karna
    Site status: Not listed — confirm with the team
  • Study Site
    Mangalore, Karna
    Site status: Not listed — confirm with the team
  • Study Site
    Mangalore, Karna
    Site status: Not listed — confirm with the team
  • Study Site
    Pune, Mahara
    Site status: Not listed — confirm with the team
  • Study Site
    Chennai, Tamil Nadu
    Site status: Not listed — confirm with the team
  • Study Site
    Varanasi, Uttar Prad
    Site status: Not listed — confirm with the team
Philippines · 2 sites
  • Study Site
    Cebu City
    Site status: Not listed — confirm with the team
  • Study Site
    Mandaluyong
    Site status: Not listed — confirm with the team
Romania · 7 sites
  • Study Site
    Arad
    Site status: Not listed — confirm with the team
  • Study Site
    Bucharest
    Site status: Not listed — confirm with the team
  • Study Site (1)
    Bucharest
    Site status: Not listed — confirm with the team
  • Study Site (2)
    Bucharest
    Site status: Not listed — confirm with the team
  • Study Site (3)
    Bucharest
    Site status: Not listed — confirm with the team
  • Study Site
    Cluj-Napoca
    Site status: Not listed — confirm with the team
  • Study Site
    Oradea
    Site status: Not listed — confirm with the team
Russia · 6 sites
  • Study Site
    Moscow
    Site status: Not listed — confirm with the team
  • Study Site
    Moscow
    Site status: Not listed — confirm with the team
  • Study Site
    Moscow Region
    Site status: Not listed — confirm with the team
  • Study Site
    Saint Petersburg
    Site status: Not listed — confirm with the team
  • Study Site
    Saint Petersburg
    Site status: Not listed — confirm with the team
  • Study Site
    Saint Petersburg
    Site status: Not listed — confirm with the team
Serbia · 4 sites
  • Study Site (1)
    Belgrade
    Site status: Not listed — confirm with the team
  • Study Site (2)
    Belgrade
    Site status: Not listed — confirm with the team
  • Study Site
    Kragujevac
    Site status: Not listed — confirm with the team
  • Study Site
    Novi Sad
    Site status: Not listed — confirm with the team
Slovakia · 5 sites
  • Study Site
    Bojnice
    Site status: Not listed — confirm with the team
  • Study Site
    Bratislava
    Site status: Not listed — confirm with the team
  • Study Site
    Liptovský Mikuláš
    Site status: Not listed — confirm with the team
  • Study Site
    Rimavská Sobota
    Site status: Not listed — confirm with the team
  • Study Site
    Žilina
    Site status: Not listed — confirm with the team
South Korea · 5 sites
  • Study Site
    Busan
    Site status: Not listed — confirm with the team
  • Study Site
    Chuncheon
    Site status: Not listed — confirm with the team
  • Study Site
    Incheon
    Site status: Not listed — confirm with the team
  • Study Site
    Incheon
    Site status: Not listed — confirm with the team
  • Study Site
    Seoul
    Site status: Not listed — confirm with the team
Taiwan · 2 sites
  • Study Site
    Hualien Town
    Site status: Not listed — confirm with the team
  • Study Site
    Taipei
    Site status: Not listed — confirm with the team
Ukraine · 8 sites
  • Study Site
    Chernihiv
    Site status: Not listed — confirm with the team
  • Study Site
    Dnipropetrovsk
    Site status: Not listed — confirm with the team
  • Study Site
    Kherson,Vil. Stepanivka
    Site status: Not listed — confirm with the team
  • Study Site
    Kyiv
    Site status: Not listed — confirm with the team
  • Study Site
    Kyiv
    Site status: Not listed — confirm with the team
  • Study Site
    Kyiv
    Site status: Not listed — confirm with the team
  • Study Site
    Simferopol
    Site status: Not listed — confirm with the team
  • Study Site
    Vinnitsia
    Site status: Not listed — confirm with the team
United States · 16 sites
  • Study Site
    Little Rock, Arkansas
    Site status: Not listed — confirm with the team
  • Study Site
    Escondido, California
    Site status: Not listed — confirm with the team
  • Study Site
    Garden Grove, California
    Site status: Not listed — confirm with the team
  • Study Site
    Long Beach, California
    Site status: Not listed — confirm with the team
  • Study Site
    Oceanside, California
    Site status: Not listed — confirm with the team
  • Study Site
    Pasadena, California
    Site status: Not listed — confirm with the team
  • Study Site
    San Diego, California
    Site status: Not listed — confirm with the team
  • Study Site
    San Diego, California
    Site status: Not listed — confirm with the team
  • Study Site
    Santa Ana, California
    Site status: Not listed — confirm with the team
  • Study Site
    Washington D.C., District of Columbia
    Site status: Not listed — confirm with the team
  • Study Site
    Bradenton, Florida
    Site status: Not listed — confirm with the team
  • Study Site
    Maitland, Florida
    Site status: Not listed — confirm with the team
  • Study Site
    St Louis, Missouri
    Site status: Not listed — confirm with the team
  • Study Site
    Cedarhurst, New York
    Site status: Not listed — confirm with the team
  • Study Site
    Philadelphia, Pennsylvania
    Site status: Not listed — confirm with the team
  • Study Site
    Austin, Texas
    Site status: Not listed — confirm with the team
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving OPC-34712, Placebo, Aripiprazole. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.

Who might this study be for?

This study may concern people with schizophrenia; age range: From 18 Years to 65 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc., which appears to be a pharmaceutical company. Sponsor website: https://www.otsuka.co.jp/en/. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me